Regulatory · Reviewed 2026-06-04

Is Compounded Semaglutide FDA-Approved?

The honest answer is no — and the rules around who may compound it changed sharply in 2025–2026. Here is the current picture.

Quick Answer

Compounded semaglutide is not an FDA-approved finished drug product. Branded Wegovy and Ozempic are FDA-approved. The FDA declared the semaglutide shortage resolved in February 2025, which ended the broad shortage-based allowance for mass compounding; patient-specific compounding by licensed pharmacies continues under a separate legal framework, and large-scale 503B compounding is under active regulatory pressure in 2026.

Key Facts

Compounded semaglutide is not FDA-approved; only branded semaglutide products (Wegovy, Ozempic) are.
The FDA removed semaglutide from its shortage list in February 2025, triggering a phase-out of mass compounding.
Patient-specific (503A) compounding continues when prepared per a valid individual prescription at a licensed pharmacy.
In April 2026 the FDA proposed removing semaglutide from the 503B outsourcing-facility bulks list; the proposal has been open for public comment and remains contested in court.
Salt forms such as semaglutide sodium are unapproved; the FDA-recognized active form is semaglutide base.

Why this matters for price: The legal landscape is shifting in 2026. No provider can legally guarantee uninterrupted compounded supply, and unusually low prices can signal regulatory risk or non-compliant products. Verify the pharmacy and the active form before relying on any program.

503A vs. 503B in plain terms

503A pharmacies prepare a medication for a specific patient under an individual prescription — a long-standing pathway that does not depend on the shortage list. 503B outsourcing facilities produce larger batches and are the focus of the FDA’s 2026 bulks-list proposal. The distinction affects both legality and where a given program’s product comes from.

What to Verify

That the fulfilling pharmacy is named, state-licensed, and identifiable as 503A or 503B.
That the product is semaglutide base, not an unapproved salt form.
The current legal status, which is changing — check the FDA and our news hub for updates.
That the provider is not promising guaranteed supply or guaranteed results.

Bottom Line

Treat “FDA-approved compounded semaglutide” as a red flag — it does not exist. Compounded semaglutide can be legal when prescribed and prepared appropriately for an individual patient, but the rules are tightening in 2026. Confirm the pharmacy, the active form, and current legality, and decide with a licensed prescriber.

Compounded semaglutide is not FDA-approved as a finished drug product. Compounded medications may be prescribed only when clinically appropriate and must be evaluated by a licensed prescriber. Branded medications such as Wegovy and Ozempic are FDA-approved products; compounded semaglutide is different and should not be described as FDA-approved, “generic Wegovy,” or “generic Ozempic.”